Total for the last 12 months
number of access : ?
number of downloads : ?
ID 119174
Author
Bando, Hiroshi Medical Research|Tokushima University|Japan Low Carbohydrate Diet Promotion Association|Yoshinogawa Hospital KAKEN Search Researchers
Kobayashi, H Yoshinogawa Hospital
Ogawa, H Yoshinogawa Hospital
Nakanishi, M Yoshinogawa Hospital
Watanabe, O Yoshinogawa Hospital
Keywords
imeglimin (Twymeeg)
pre-prandial blood glucose
post-prandial blood glucose
Trials of IMeglimin for Efficacy and Safety (TIMES)
oral hypoglycemic agent (OHA)
Content Type
Journal Article
Description
As recent topic for oral hypoglycemic agent (OHA), imeglimin (Twymeeg) shows clinical efficacy. Current case is 77-year-old female with type 2 diabetes (T2D) for years. HbA1c increased to 8.4% in Jan, 2023 and then Twymeeg was initiated. She has continued detail measurement of pre-prandial glucose 3 times a day, and these data were analyzed during Dec 2022 to Feb 2023. As a result, HbA1c decreased to 7.9% in 5 weeks, and pre-prandial level has decreased in satisfactory degree. In contrast, she kept intake of certain amount of carbohydrates in 3 meals as usual, and post-prandial hyperglycemia has been stable.
Journal Title
International Journal of Endocrinology and Diabetes
ISSN
26943875
Publisher
Pubtexto Publishers
Volume
6
Issue
1
Start Page
147
Published Date
2023-03-11
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences
University Hospital